Alnylam to Webcast Presentations at Upcoming Investor Conferences
07 November 2018 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
company overviews at the following conferences:
- Stifel 2018 Healthcare Conference on
Wednesday, November 14, 2018 at 10:15 am ET at the Lotte New York
Palace Hotel in New York City
- 27th Annual Credit Suisse Healthcare
Conference on Wednesday, November 14, 2018 at 3:25 pm MT (5:25 pm
ET) at the Phoenician Hotel in Scottsdale, Arizona
A live audio webcast of each presentation will be available on
the Investors section of the Company’s website, www.alnylam.com. A
replay will be available on the Alnylam website within 48 hours
after each event.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class
of innovative medicines with the potential to improve the lives of
people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS) diseases. Based on
Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of severe and debilitating diseases. Founded in 2002, Alnylam
is delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform. ONPATTRO™ (patisiran)
lipid complex injection, available in the U.S. for the treatment of
the polyneuropathy of hereditary transthyretin-mediated (hATTR)
amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi
therapeutic. In the EU, ONPATTRO is approved for the treatment of
hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy.
Alnylam has a deep pipeline of investigational medicines, including
three product candidates that are in late-stage development.
Looking forward, Alnylam will continue to execute on its "Alnylam
2020" strategy of building a multi-product, commercial-stage
biopharmaceutical company with a sustainable pipeline of RNAi-based
medicines to address the needs of patients who have limited or
inadequate treatment options. Alnylam employs over 800 people
worldwide and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at
@Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181106005898/en/
Alnylam Pharmaceuticals, Inc.(Investors and
Media)Christine Regan Lindenboom, 617-682-4340or(Investors)Josh
Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024